DIA Annual Meeting, Washington, D.C. and Boston, Mass., June 16, 2015-- BBK Worldwide
http://bbkworldwide.com/
, a leading clinical trial marketing firm, today announced the availability of RSG® Arrive, a full-service concierge program created to more fully support clinical trial patients and operationalize travel for pharmaceutical companies, especially important for rare disease studies where recruitment of patients extends well beyond the area of the site, often in different countries. The latest offering within the company's RSG® Suite<
http://www.rsgsuite.com/
> of engagement services, RSG Arrive leverages industry best practices to offer streamlined adherence and workflows, all at a reduced cost. The program has been implemented across several global studies, and sponsor and patient feedback has been overwhelmingly positive. Designed to optimize the millions of dollars spent on study-related care annually and support the demands inherent in today's growing personalized approach to research, RSG Arrive manages all travel-related logistics operational and financial for trial patients and sites. From car and shuttle booking, to international flight and accommodation management, RSG Arrive ensures that patients get to and from study visits as simply and seamlessly as possible; removing what can be a heavy burden for study patients and the study teams supporting them. RSG Arrive can also provide complementary services for patients requiring additional support, as well as offer sponsors a turn-key solution to streamline retention efforts at the site level. "With few to no options available to them, those suffering from the most devastating of illnesses are often unable to participate in clinical research because the few highly specialized physician investigators are simply too far away," said Jaime Cohen, strategic consultation and research, BBK Worldwide. "The goal is two-fold to ensure that patients participating in clinical trials have the support they need, and to remove what can be a primary and costly and ultimately unnecessary study enrollment barrier." Additionally, because the program leverages BBK¹s cloud-based patient recruitment platform all travel logistics are linked to individual patient and study visits and are updated and available in real-time, providing clarity and saving study teams valuable time, budget and resources all within a secure and confidential environment.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
VERITAC-2 Trial Shows Vepdegestrant Significantly Improves Survival in ESR1-Mutant Breast Cancer
March 24th 2025Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant in patients with ESR1-mutant (ESR1m) advanced or metastatic breast cancer, but did not achieve statistical significance in the overall intent-to-treat population.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.